These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38129745)

  • 1. Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.
    Dubey S; Mishra N; Shelke R; Varma AK
    FEBS J; 2024 Apr; 291(7):1422-1438. PubMed ID: 38129745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
    Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
    Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
    Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal approach to characterize the tetrameric form of human PML-RBCC domain and ATO-mediated conformational changes.
    Dubey S; Mishra N; Goswami N; Siddiqui MQ; Varma AK
    Int J Biol Macromol; 2022 Dec; 223(Pt A):468-478. PubMed ID: 36356867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function of PML-RARA in Acute Promyelocytic Leukemia.
    Testa U; Pelosi E
    Adv Exp Med Biol; 2024; 1459():321-339. PubMed ID: 39017850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
    Bercier P; Wang QQ; Zang N; Zhang J; Yang C; Maimaitiyiming Y; Abou-Ghali M; Berthier C; Wu C; Niwa-Kawakita M; Dirami T; Geoffroy MC; Ferhi O; Quentin S; Benhenda S; Ogra Y; Gueroui Z; Zhou C; Naranmandura H; de Thé H; Lallemand-Breitenbach V
    Cancer Discov; 2023 Dec; 13(12):2548-2565. PubMed ID: 37655965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a point mutation PML
    Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
    Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
    Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities.
    Rérolle D; Wu HC; de Thé H
    Cold Spring Harb Perspect Med; 2024 Sep; 14(9):. PubMed ID: 38503502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
    Jo S; Lee YL; Kim S; Lee H; Chung H
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
    Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
    Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
    Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
    Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelling Bodies: Understanding the Mechanisms Underlying Arsenic Trioxide Action.
    Salomoni P
    Cancer Discov; 2023 Dec; 13(12):2505-2506. PubMed ID: 38084094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.